AbbVie Inc (ABBV)vsConcentra Group Holdings Parent, Inc. (CON)
ABBV
AbbVie Inc
$265.36
+0.28%
HEALTHCARE · Cap: $454.36B
CON
Concentra Group Holdings Parent, Inc.
$34.88
+0.32%
HEALTHCARE · Cap: $4.52B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2715% more annual revenue ($64.39B vs $2.29B). ABBV leads profitability with a 9.8% profit margin vs 8.7%. CON trades at a lower P/E of 22.9x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
CON
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$265.36
$113.20 premium
Intrinsic value data unavailable for CON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 42 in profit
Earnings expanding 47.0% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 9.3x book value
Weak financial health signals
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : CON
The strongest argument for CON centers on Return on Equity, EPS Growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : CON
The primary concerns for CON are Price/Book, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 4.49 is elevated, increasing financial risk.
Key Dynamics to Monitor
CON carries more volatility with a beta of 0.63 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 61/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Concentra Group Holdings Parent, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Concentra Group Holdings Parent, Inc. (Ticker: CON) is a diversified holding company strategically focused on acquiring and managing businesses across high-growth sectors, including healthcare, technology, and infrastructure. With a robust leadership team committed to operational excellence and innovation, Concentra actively seeks to optimize its portfolio through strategic investments and management practices. This proactive approach enables Concentra to effectively leverage emerging market trends and growth opportunities, making it a compelling choice for institutional investors seeking diversification in dynamic and high-potential markets.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?